4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $28.56 Average Price Target from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $28.5556.

Several research analysts have weighed in on the company. Cantor Fitzgerald raised 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target on the stock in a research report on Monday, September 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. The Goldman Sachs Group restated a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Finally, Chardan Capital upgraded shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th.

Insider Activity at 4D Molecular Therapeutics

In other news, insider David Kirn sold 58,333 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $13.90, for a total transaction of $810,828.70. Following the transaction, the insider directly owned 767,486 shares in the company, valued at $10,668,055.40. The trade was a 7.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 134,570 shares of company stock valued at $1,743,197. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently bought and sold shares of the company. Legal & General Group Plc acquired a new stake in shares of 4D Molecular Therapeutics in the second quarter valued at approximately $59,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth approximately $148,000. Gabelli Funds LLC acquired a new position in shares of 4D Molecular Therapeutics during the 4th quarter worth approximately $90,000. The Manufacturers Life Insurance Company acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth approximately $166,000. Finally, Sei Investments Co. raised its stake in 4D Molecular Therapeutics by 8.9% in the 1st quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock valued at $120,000 after acquiring an additional 1,050 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Trading Up 4.2%

Shares of NASDAQ:FDMT opened at $15.88 on Friday. The company’s 50-day moving average price is $12.95 and its two-hundred day moving average price is $10.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. 4D Molecular Therapeutics has a one year low of $6.96 and a one year high of $16.93. The stock has a market capitalization of $877.21 million, a PE ratio of -6.04 and a beta of 2.74.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. On average, equities analysts forecast that 4D Molecular Therapeutics will post -4.07 EPS for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.